Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura

International Journal of Hematology

Volumn 81, Issue 5, 2005, Pages 433-436

  Kosugi, Satoru ^a   Matsumoto, Masanori ^b   Ohtani, Yasushi ^a   Take, Hironori ^a   Ishizashi, Hiromichi ^b   Fujimura, Yoshihiro ^b   Kuyama, Jun ^a  

^a TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti ADAMTS13 autoantibody; Rituximab; Thrombotic thrombocytopenic purpura (TTP); Von Willebrand factor cleaving protease (VWF CP)

Indexed keywords

AUTOANTIBODY; ENZYME ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

AGED; ARTICLE; CASE REPORT; HUMAN; LONG TERM CARE; MALE; PLASMAPHERESIS; REFRACTORY PERIOD; RELAPSE; REMISSION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADAM PROTEINS; AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; METALLOENDOPEPTIDASES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 21444452605     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04187     Document Type: Article

References (23)

1. Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Prog Hemost Thromb. 1982;6:287-337.
2. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
3. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
5. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397.
6. Shumak KH, Rock GA, Nair RC. Late relapse in patients successfully treated for thrombotic thrombocytopenic purpura: Canadian Apheresis Group. Ann Intern Med. 1995;44:2836-2840.
7. Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol. 1997;34:134-139.
8. Kuwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34:159-166.
9. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556-573.
10. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis. 2003;18:51-54.
11. Hovinga JAK, Studt JD, Biasiutti FD, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2004;89:320-324.
12. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
13. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999; 52:1701-1704.
14. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
15. Remmuzzi G, Chiuruchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360:923-924.
16. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385-391.
17. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105-108.
18. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105-108.
19. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183-185.
20. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124: 787-795.
21. Stein YG, Aeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol. 2004;80:94-96.
22. Sugio Y, Okamura T, Shimoda K, et al. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol. 2001;74:347-351.
23. Kawahara M, Kanno M, Matsumoto M, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. Neurology. 2004;63:1731-1733.